Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
Jingran Ji(Northwestern University), Jonathan W. Riess(University of California Davis Medical Center), Collin M. Blakely(City College of San Francisco), Laura A. Huppert(University of California, San Francisco), Andrew J. Piper‐Vallillo(Harvard University), Hatim Husain(University of California, San Diego), Caroline E. McCoach(Memorial Sloan Kettering Cancer Center), Joel W. Neal(Stanford Medicine), Heather A. Wakelee(Palo Alto Institute), Subba R. Digumarthy(Massachusetts General Hospital), Matthew A. Gubens(University of California, San Francisco), Jacqueline V. Aredo(Stanford University), Mohammad Hamidi Madani(UC Davis Comprehensive Cancer Center), Zofia Piotrowska(Global Cancer Institute), Melisa L. Wong(UCSF Helen Diller Family Comprehensive Cancer Center), Rosemary Cobb(Massachusetts General Hospital), Susan Stewart(Stiftung Wissenschaft und Politik, German Institute for International and Security Affairs), Julia Rotow(University of California, San Francisco)
Cited by 39
Related Papers
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells
|New England Journal of Medicine|2008|1.6k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k